|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the crosstalk between YAP1 and mTOR and its role in bladder cancer progression remains unclear.
|
31789387 |
2020 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mammalian target of rapamycin (mTOR) and associated phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway is commonly up-regulated in cancer, including bladder cancer. mTOR complex 2 (mTORC2) is a major regulator of bladder cancer cell migration and invasion, but the mechanisms by which mTORC2 regulates these processes are unclear.
|
31199921 |
2019 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
To address the translational relevance of these findings, the effects of the mTOR complex 1 (mTORC1) inhibitor, rapamycin, on tumor and T cells were monitored in patients undergoing cystectomy for bladder cancer.
|
30563829 |
2019 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although mechanistic target of rapamycin (mTOR) inhibitors, such as temsirolimus, show promise in treating bladder cancer, acquired resistance often hampers efficacy.
|
31167517 |
2019 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
These suggested that miR-99a-5p/mTOR axis might be a therapeutic target for bladder cancer.
|
30560585 |
2019 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.
|
29375709 |
2018 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggested that OA induced protective autophagy through AMPK-mTOR-ULK1 signaling pathway in bladder cancer cells and OA in combination with autophagy inhibitor might be a novel alternative for the treatment of bladder cancer.
|
28978086 |
2017 |
|
Carcinoma of bladder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we focused on mechanistic target of rapamycin (mTOR) inhibition as a chemotherapeutic strategy and characterized the expression profile of mTOR signaling targets in representative bladder cancer cell lines from basal, luminal, and either basal/luminal ("non-type") molecular subtypes.
|
28427860 |
2017 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mammalian target of rapamycin complex 2 (mTORC2) has been identified as a major regulator of bladder cancer cell migration and invasion.
|
27777073 |
2017 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We thus hypothesized that the use of autophagy inhibitor in combination with mTOR inhibition improves the cytotoxicity of mTOR inhibitors in bladder cancer.
|
27143856 |
2016 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations in the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway are frequent in urothelial bladder cancer (BLCA) and thus provide a potential target for novel therapeutic strategies.
|
25349966 |
2014 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bioinformatic analysis showed that the mTOR gene was a direct target of miR-100. siRNA-mediated mTOR knockdown phenocopied the effect of miR-100 in bladder cancer cell lines.
|
23270926 |
2013 |
|
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results provide the first strong evidence that physical activity, energy intake, and genetic variants in the mTOR pathway jointly influence bladder cancer susceptibility and that these results have implications for bladder cancer prevention.
|
20354165 |
2010 |
|
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease.
|
19261747 |
2009 |
|
Carcinoma of bladder
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|